88 related articles for article (PubMed ID: 17680507)
1. What should the cardiologist tell the patient facing revascularization for three-vessel disease?
Mickley H
Scand Cardiovasc J; 2007 Aug; 41(4):212-3. PubMed ID: 17680507
[No Abstract] [Full Text] [Related]
2. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
3. Utility of cardiac MRI in guiding revascularization therapy in unprotected left main stenosis: a case report.
Suh WM; Fowler SJ; Wallis JB; Kern MJ; Ahsan CH
Cardiovasc Revasc Med; 2007; 8(3):209-12. PubMed ID: 17765652
[TBL] [Abstract][Full Text] [Related]
4. Surgery or percutaneous coronary intervention for three-vessel and left main coronary artery disease: a critical appraisal of the literature.
Alison P; Sidebotham D
N Z Med J; 2007 Jun; 120(1255):U2557. PubMed ID: 17546105
[No Abstract] [Full Text] [Related]
5. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
[TBL] [Abstract][Full Text] [Related]
6. Revascularization of unprotected left main coronary artery disease with percutaneous coronary intervention: the role of drug-eluting stents.
Kirtane AJ; Chieffo A; Magni V; Mehran R; Colombo A; Moses JW
Minerva Cardioangiol; 2008 Feb; 56(1):43-53. PubMed ID: 18432168
[TBL] [Abstract][Full Text] [Related]
7. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards.
Kandzari DE; Colombo A; Park SJ; Tommaso CL; Ellis SG; Guzman LA; Teirstein PS; Tamburino C; Ormiston J; Stone GW; Dangas GD; Popma JJ; Bass TA;
J Am Coll Cardiol; 2009 Oct; 54(17):1576-88. PubMed ID: 19833256
[TBL] [Abstract][Full Text] [Related]
8. Myocardial infarction and the open-artery hypothesis.
Hillis LD; Lange RA
N Engl J Med; 2006 Dec; 355(23):2475-7. PubMed ID: 17105760
[No Abstract] [Full Text] [Related]
9. Marine n-3 polyunsaturated fatty acids and coronary heart disease: Part II. clinical trials and recommendations.
Schmidt EB; Arnesen H; Christensen JH; Rasmussen LH; Kristensen SD; De Caterina R
Thromb Res; 2005; 115(4):257-62. PubMed ID: 15668184
[No Abstract] [Full Text] [Related]
10. Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment.
Kamphuisen PW
Eur Heart J; 2008 Jul; 29(14):1699-700. PubMed ID: 18544543
[No Abstract] [Full Text] [Related]
11. Successful emergent surgical revascularization and retrieval of entrapped drug eluting stent.
Bruschi G; Colombo P; Piccalò G; Trunfio S; Colombo T; Vitali E
J Cardiovasc Med (Hagerstown); 2008 Feb; 9(2):182-3. PubMed ID: 18192812
[TBL] [Abstract][Full Text] [Related]
12. Should we revascularize patients with moderate coronary lesions and borderline fractional flow reserve measurements?
Zijlstra F
Catheter Cardiovasc Interv; 2008 Mar; 71(4):549-50. PubMed ID: 18307225
[No Abstract] [Full Text] [Related]
13. What physicians should know about coronary stents.
Rihal CS
Minn Med; 2008 Jan; 91(1):44-6. PubMed ID: 18269069
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous revascularization is the preferred strategy for patients with significant left main coronary stenosis.
Teirstein PS
Circulation; 2009 Feb; 119(7):1021-33. PubMed ID: 19237673
[No Abstract] [Full Text] [Related]
15. Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies.
Haeck JD; Verouden NJ; Henriques JP; Koch KT
Future Cardiol; 2009 Jul; 5(4):385-402. PubMed ID: 19656063
[TBL] [Abstract][Full Text] [Related]
16. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction: DECOPI or NOT DECOPI: more smoke on the horizon.
Achrafi H
Eur Heart J; 2005 Aug; 26(15):1566-7; author reply 1567-8. PubMed ID: 15958436
[No Abstract] [Full Text] [Related]
17. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
18. "Anti-healing" versus "pro-healing".
Seth DA
Catheter Cardiovasc Interv; 2008 Apr; 71(5):605-6. PubMed ID: 18360850
[No Abstract] [Full Text] [Related]
19. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
Anselmino M; Malmberg K; Ohrvik J; Rydén L;
Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
